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Abstract
Background: Epidemiological studies substantiated that subjects with elevated lipoprotein(a) [Lp(a)] have a markedly
increased cardiovascular risk. Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) lowers both LDL
cholesterol (LDL-C) as well as Lp(a), albeit modestly. Effects of PCSK9 inhibition on circulating metabolites such as
lipoprotein subclasses, amino acids and fatty acids remain to be characterized.
Methods: We performed nuclear magnetic resonance (NMR) metabolomics on plasma samples derived from 30
individuals with elevated Lp(a) (> 150mg/dL). The 30 participants were randomly assigned into two groups, placebo
(N = 14) and evolocumab (N = 16). We assessed the effect of 16 weeks of evolocumab 420mg Q4W treatment on
circulating metabolites by running lognormal regression analyses, and compared this to placebo. Subsequently, we
assessed the interrelationship between Lp(a) and 14 lipoprotein subclasses in response to treatment with evolocumab,
by running multilevel multivariate regression analyses.
Results: On average, evolocumab treatment for 16 weeks resulted in a 17% (95% credible interval: 8 to 26%, P < 0.001)
reduction of circulating Lp(a), coupled with substantial reduction of VLDL, IDL and LDL particles as well as their lipid
contents. Interestingly, increasing concentrations of baseline Lp(a) were associated with larger reduction in triglyceride-
rich VLDL particles after evolocumab treatment.
Conclusions: Inhibition of PCSK9 with evolocumab markedly reduced VLDL particle concentrations in addition to
lowering LDL-C. The extent of reduction in VLDL particles depended on the baseline level of Lp(a). Our findings
suggest a marked effect of evolocumab on VLDL metabolism in subjects with elevated Lp(a).
Trial registration: Clinical trial registration information is registered at ClinicalTrials.gov on April 14, 2016 with the
registration number NCT02729025.
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Background
Lipoprotein(a) [Lp(a)], synthesized in the liver, is a low-
density lipoprotein (LDL)-like particle covalently bound
to the apolipoprotein(a) [apo(a)]. Lp(a) is cleared from
the circulation primarily by the liver [1], but the exact
mechanism remains to be elucidated. Epidemiological
studies substantiated a markedly increased cardiovascu-
lar risk in subjects with elevated Lp(a), involving both
pro-inflammatory as well as pro-coagulant effects [2]. To
date, limited therapeutic options are available to reduce
Lp(a) in plasma [3]. One agent that lowers Lp(a) levels is
proprotein convertase subtilisin/kexin type 9 (PCSK9)
monoclonal antibody, resulting in increased abundance
of LDL receptors [4, 5]. The excess number of LDL re-
ceptors on the surface of hepatocytes may contribute to
enhanced Lp(a) catabolism [5, 6]. However, this concept
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is not supported by the effect of statin therapy, which
also increases abundance of the hepatic LDL receptor
with a concomitant increase of plasma Lp(a) [7]. Hence,
the exact role of the LDL-receptor in Lp(a) catabolism
remains a matter of debate [8–10].
Besides the LDL receptor, PCSK9 also induces the
degradation of the VLDL (very low density lipopro-
tein) receptor, ApoER2 (apolipoprotein E receptor 2),
and CD36 (cluster of differentiation 36) [11, 12].
Interestingly, the VLDL receptor and CD36 are recep-
tors for triglyceride-rich lipoproteins (TRLs) as well
as Lp(a), indicating a potential interaction between
Lp(a) and TRL metabolism [13–15]. A link between
Lp(a) and TRL metabolism is supported by a recent
NMR (nuclear magnetic resonance) metabolomics
study, in which a Lp(a)-raising genotype was found to
associate with decreasing concentrations of
triglyceride-rich VLDL particles [16]. The mechanism
underlying this inverse relationship is unknown. An-
other NMR metabolomics study showed that genetic
inhibition of PCSK9 and statin therapy had similar ef-
fects on circulating metabolites [17]. However, genetic
inhibition of PCSK9 differs from inhibition with a
monoclonal antibody, since genetic inhibition includes
intracellular functions of PCSK9. Moreover, data on
the relationship between Lp(a) lowering and metabol-
ism of other lipoproteins are scarce.
The aim of the current study was to investigate meta-
bolic effects of PCSK9 inhibition (evolocumab) in pa-
tients with elevated Lp(a). To this end, we studied 30
subjects with elevated Lp(a), using either placebo (n =
14) or the PCSK9 inhibitor (evolocumab, n = 16). We an-
alyzed NMR metabolomics of plasma derived from these
participants at baseline and 16 weeks after treatment.
We found that evolocumab had a marked effect on
VLDL metabolism in subjects with elevated Lp(a).
Methods
Study design
This was a substudy of the ANITSCHKOW trial
(NCT02729025) conducted at the Amsterdam UMC in
The Netherlands between April 2016 and July 2017. The
ANITSCHKOW trial was a phase 3b, multicenter, ran-
domized, double-blind, placebo-controlled trial using
subcutaneous injections of evolocumab 420 mg Q4W for
16 weeks as investigational product [18]. The current
study was based on 30 patients (placebo N = 14, evolocu-
mab N = 16). Written informed consent was obtained
from each patient included in the study. The study
protocol conforms to the ethical guidelines of the Dec-
laration of Helsinki. The study protocol was approved by
the ethic committee of the Amsterdam UMC.
The complete list of eligibility criteria for the
ANITSCHKOW trial were:
 Inclusion criteria
– Patient has provided written informed consent
prior to initiation of any study specific activities/
procedures
– Male or female, ≥ 50 years of age at the time of
informed consent
– Fasting Lp(a) ≥ 125 nmol/L (50 mg/dL)
– Fasting LDL-C ≥ 2.6 mmol/L (100 mg/dL)
– For patients receiving lipid-lowering therapy (not
required to participate in this study), lipid-
lowering therapy, including statin dose, must be
unchanged for ≥ 8 weeks prior to screening
TBRmax above 1.6 (either right carotid, left ca-
rotid or thoracic aorta) on FDG-PET/CT
 Exclusion criteria
– Currently receiving, or < 4 weeks since receiving,
treatment in another investigational device or
drug study(ies), or participating in other
investigational procedures
– Known diagnosis of diabetes mellitus or screening
fasting serum glucose ≥ 7 mmol/L or glycated
haemoglobin (HbA1c) ≥ 6.5%
– History of homozygous familial
hypercholesterolemia
– Recent cardiovascular event (myocardial
infarction, unstable angina, percutaneous
coronary intervention [PCI], coronary artery
bypass graft, or stroke) within 3 months prior
to randomization, or planned cardiac surgery,
PCI or carotid stenting, or planned major non-
cardiac surgery during the course of the study
period
– Currently undergoing lipid apheresis
– Known contraindications or limitations to FDG-
PET/CT (eg, scanner weight limit, devices that
can cause image artifacts, or carotid/aortic stents/
grafts)
– Autoimmune disease/vasculitis, active
inflammatory diseases, proven or suspected
bacterial infections
– Recent (< 1 month prior to screening) or ongoing
serious infection requiring intravenous antibiotic
therapy
– Recent (< 6 weeks prior to screening) or current
treatment with medications that may have a
significant effect on plaque inflammation as
measured by plaque TBR, including: oral, rectal,
or injectable corticosteroids or
immunosuppressive medications (eg,
cyclosporine, methotrexate, tacrolimus,
azathioprine, anti-thymocyte globulin, sirolimus,
anti-tumour necrosis factor agents such as inflixi-
mab, anti-interleukin [IL] 6 therapy such as toci-
lizumab, or anti-IL1 therapy)
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– Recent (< 6 weeks prior to screening) or current
treatment with aspirin (> 325 mg/day) or
nonsteroidal anti-inflammatory drugs (NSAIDs)
(> 1000 mg/day)
– Known sensitivity to any of the active substances
or excipients (eg, carboxymethylcellulose) to be
administered during dosing
– Treatment with a cholesterol ester transfer
protein inhibitor (eg, anacetrapib, dalcetrapib,
evacetrapib) or mipomersen or lomitapide in the
last 12 months prior to screening
– Known systemic disorders such as hepatic, renal,
hematologic, and malignant diseases or any
clinically significant medical condition that could
interfere with the conduct of the study
– History of malignancy (except non-melanoma
skin cancers, cervical in-situ carcinoma, breast
ductal carcinoma in situ, or stage 1 prostate car-
cinoma) within the last 5 years
– Patients likely to not be available to complete all
protocol-required study visits or procedures, or
unreliability as a study participant (eg, alcohol or
other drug abuse in the past year or psychosis),
to the best of the patient’s and investigator’s
knowledge
– History or evidence of any other clinically
significant disorder, condition or disease that, in
the opinion of the investigator or sponsor
physician, if consulted, would pose a risk to
subject safety or interfere with the study
evaluation, procedures, or completion
– Prior treatment with evolocumab or any other
therapy to inhibit PCSK9
– Pregnant or breastfeeding or planning to become
pregnant or breastfeed during treatment with
study drug and for an additional 15 weeks after
the last dose of study drug
Biochemical measurements
Blood samples were obtained at time of randomization
and 16 weeks after treatment. Patients were fasting for ≥
9 h for both blood withdrawals. Total cholesterol, high-
density lipoprotein (HDL) cholesterol, triglycerides, and
apolipoproteinB-100 (ApoB-100) were measured by
commercially available kits at the Medpace core lab
(Medpace Reference Laboratories, Leuven, Belgium).
Low-density lipoprotein (LDL) cholesterol was calcu-
lated using the Friedewald formula. Ultracentrifugation-
determined LDL-C was measured and reported if calcu-
lated LDL cholesterol was below 40 mg/dL, or triglycer-
ides were above 400 mg/dL. Lipoprotein(a) levels were
measured using an isoform-independent immunoturbi-
dometric assay (Polymedco, Cortlandt Manor, NY, USA)
and reported in nmol/L.
Metabolite quantification
Quantification of 225 metabolic measures was per-
formed by using a high-throughput NMR metabolomics
platform (Nightingale health, Finland) [19]. The 225
metabolic measures contain around 150 primary con-
centrations as well as ratios that were derived from the
primary concentrations. In this study, we focused on pri-
mary concentrations of circulating metabolites that
cover multiple metabolic pathways including lipopro-
teins, fatty acids as well as amino acids and glycolysis in-
termediates. The following 14 lipoprotein subclasses and
their lipid compositions were quantified: extremely large
(average particle diameter > 75 nm), very large (average
particle diameter 64.0 nm), large (53.6 nm), medium
(44.5 nm), small (36.8 nm) and very small VLDL (31.3
nm); intermediate density lipoprotein (IDL; 28.6 nm);
three LDL subclasses, i.e. large (25.5 nm), medium (23.0
nm) and small LDL (18.7 nm); and four HDL subclasses,
i.e. very large (14.3 nm), large (12.1 nm), medium (10.9
nm) and small HDL (8.7 nm). The complete list of the
225 metabolic measures can be found at https://nightin-
galehealth.com/biomarkers
Statistical analysis
Metabolic effects of PCSK9 inhibition with evolocumab
To assess the effect of evolocumab on levels of a circu-
lating metabolite, we ran lognormal regression analysis.
The outcome variable (y) was the concentration of a me-
tabolite. Two predictor variables were in the regression
model: 1) evolocumab treatment (evolocumab, Ti = 1;
placebo Ti = 0); 2) metabolite concentration at time of
randomization (x). To investigate potential combined ef-
fects of evolocumab and other lipid lowering drugs on
lipoproteine subclasses, we added two indicator variables
S and E. If a patient was treated with statin, then S = 1,
otherwise S = 0. Similarly, if a patient was also treated
with ezetimibe, then E = 1, otherwise E = 0. The baseline
concentrations were centered and scaled so that the
mean is 0 and standard deviation is 1. The lognormal
distribution was chosen to model the outcome variable
because its values were positive continuous. Due to
missing observations in outcome variables, we applied
the Bayesian approach to handle missing data. There
were two types of missing values: (1) when the concen-
tration of a metabolite is below the limit of detection, or
(2) when values were rejected by the automatic sample
and measurement quality control procedure in the
Nightingale pipeline. All the missing observations were
assumed missing at random and treated as parameters.
Values were randomly drawn from a lognormal distribu-
tion. Regarding the missing values that were below the
limit of detection, the imputed values were constrained
between zero and the minimal observed value. We fitted
the model by running Hamiltonian Markov Chain
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Monte Carlo in the program Stan (version 2.18.3). We
ran four Markov chains with 2000 iterations in each
chain. Results were presented with the posterior mean
with 95% credible interval (CI).
Multilevel multivariate model
To assess the relationship between Lp(a) lowering and
metabolism of 14 lipoprotein subclasses, we developed a
multilevel multivariate model. The detailed model is
available at https://github.com/XiangZhangSC/Anitsch-
kow. In short, 16 subjects from the treatment group
were used for this analysis, and each subject had two
plasma samples at time of randomization and after
treatment.
The outcome variable is a vector of 2, [Li, yi], in which
Li represents the Lp(a) concentration in sample i, and yi
represents the particle concentration of a lipoprotein
subclass in sample i. The logarithm of [Li, yi] was mod-
eled by a multivariate normal distribution, with parame-
ters μL (a vector of 32), μy (a vector of 32) and Σ (a 2-by-
2 covariance matrix). μL[i] represents the mean concen-
tration of Lp(a) in sample i, and was modeled as
μL i½  ¼ αL;subject i½  þ βL;subject i½   V 2 i½ 
αL is a vector of 16, and represents the Lp(a) abun-
dance at baseline. βL is a vector of 16, and represents the
effect of evolocumab treatment on Lp(a). V2 is a vector
of 32 with 0 s and 1 s. When V2[i] = 1, it means that
measurement was derived from the second visit (after
treatment). Otherwise, V2[i] = 0. Similarly, μy[i] repre-
sents the mean concentration of a lipoprotein subclass
in sample i, and was modeled as
μy i½  ¼ αy;subject i½  þ βy;subject i½   V 2 i½ 
αy is a vector of 16, and represents the lipoprotein sub-
class abundance at baseline. βy is a vector of 16, and rep-
resents the effect of evolocumab treatment on the
lipoprotein subclass. To assess the relationship between
the Lp(a) lowering and the metabolism of a lipoprotein
subclass, we used another multivariate normal distribu-
tion to model the subject-specific parameters.
αL; βL; αy; βy
h i
 j½ ∼MultivariateNormal θL; γL; θy; γy
h i
;Σsubj
 
θL, γL, θy, γy and Σsubj (a 4-by-4 covariance matrix) are
the hyper-parameters. We fitted the model by running
Hamiltonian Markov Chain Monte Carlo in the program
Stan (version 2.18.3). We ran four Markov chains with
2000 iterations in each chain. Results were presented
with the posterior mean with 95% credible interval (CI).
Results
Metabolic effects of PCSK9 inhibition with evolocumab
Baseline characteristics of the evolocumab and the pla-
cebo group were comparable (Table 1).
On average, evolocumab treatment for 16 weeks re-
sulted in a 17% (95% credible interval: [8, 26%]) reduc-
tion in Lp(a), together with a concomitant 67% [57, 76%]
and 21% [6, 35%] reduction in LDL cholesterol and tri-
glyceride, respectively.
To identify the metabolic effects corresponding to
PCSK9 inhibition with evolocumab, we performed NMR
metabolomics covering metabolic pathways such as lipo-
protein subclasses, fatty acids, amino acids and glycoly-
sis. We observed that evolocumab treatment resulted in
substantial reduction in particle concentration of ex-
tremely large (80% [48, 100%]), very large (90% [70,
100%]), large (60% [34, 83%]), medium (50% [36, 63%]),
small (39% [32, 46%]) and very small VLDL (47% [40,
53%]). We also observed that evolocumab treatment re-
sulted in particle concentration reduction in IDL (53%
[45, 60%]), large (56% [48, 65%]), medium (59% [50,
Table 1 Baseline characteristics
Evolocumab
(n = 16)
Placebo
(n = 14)
P value
Age, years 58.6 (7.6) 61.4 (7.5) 0.317
Gender, n male (%) 7 (44) 7 (50) 0.732
BMI, kg/m2 25.5 (3.4) 26.6 (4.0) 0.493
Smoking, n active (%) 2 (13) 0 (0) 0.171
SBP, mmHg 137 (16) 139 (12) 0.574
DBP, mmHg 82 (8) 86 (8) 0.317
CVD, n (%) 3 (19) 1 (7) 0.351
Medication use, n (%)
Statins 11 (69) 7 (50) 0.296
Ezetimibe 3 (19) 4 (29) 0.526
Total cholesterol, mmol/La 5.46 (0.92) 5.62 (0.76) 0.603
LDL-cholesterol, mmol/La 3.36 (0.70) 3.68 (0.68) 0.197
HDL-cholesterol, mmol/La 1.46 (0.43) 1.35 (0.37) 0.519
Triglycerides, mmol/Lb 1.38 [1.19–1.54] 1.28 [0.91–1.63] 0.533
ApoB, g/l 1.00 [0.93–1.15] 1.07 [0.92–1.17] 0.633
Lipoprotein(a), nmol/Lc 254 [182–297] 154 [138–300] 0.430
hs-CRP, g/l 0.75 [0.58–1.58] 1.05[0.53–1.92] 0.546
Data are mean (SD), median [interquartile range], or n (%). ApoB,
apolipoprotein B; BMI, body mass index; CVD, cardiovascular disease; DBP,
diastolic blood pressure; HDL, high-density lipoprotein; hs-CRP, high-sensitivity
C-reactive protein; LDL, low-density lipoprotein; Lp(a), lipoprotein(a); SBP,
systolic blood pressure
aTo convert to mg/dL, multiply by 38.7, b To convert to mg/dL, multiply by
88.6, c To convert to mg/dL, divide by 2.5
Wilcoxon rank-sum test was used to calculate P values for Age, BMI, SBP, DBP,
Total cholesterol, LDL-cholesterol, HDL-cholesterol, Triglycerides ApoB,
Lipoprotein(a) and hs-CRP
Chi square test was used to calculate P values for Gender, Smoking, Statins
and Ezetimibe
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67%]) and small LDL (55% [47, 64%]). In addition, we
observed that evolocumab treatment resulted in de-
creased concentrations of very large HDL particles (24%
[3, 45%]), and increased concentrations of medium HDL
particles (13% [4, 23%]) (Fig. 1).
Interestingly, we observed that evolocumab treatment
had similar effects on lipoprotein subclasses in subjects
with or without usage of lipid lowering medication.
Compared to patients treated by statin, we observed that
evolocumab treatment resulted in similar but larger ef-
fects on lipoproteins in subjects with treatment of both
statin and ezetimibe (Fig. S1).
Similar to the lipoprotein particle concentration pro-
files, we observed that evolocumab treatment resulted in
substantial reduction of esterified cholesterol (CE), tri-
glyceride (TG), free cholesterol (FC) and phospholipid
(PL) in VLDL, IDL and LDL as well as very large HDL
(Fig. S2). The NMR metabolomics also quantified the
fatty acid content in the lipoproteins. We observed that
treatment of evolocumab resulted in 30% [24, 36%] re-
duction in total fatty acids, with the largest effect on
docosahexaenoic acid (DHA 40% [24, 55%]) (Fig. S3).
We observed no difference in concentrations of other
metabolites including amino acids, fluid balance, glycoly-
sis and ketone bodies.
Relationship between Lp(a) lowering and reduction in
lipoprotein subclasses
To identify the relationship between Lp(a) lowering and
reduction in lipoprotein subclasses, we developed a
multilevel multivariate model. We observed that Lp(a)
lowering was not associated with reduction of the 14
lipoprotein subclasses (Fig. S4). Interestingly, we
observed that the reduction in medium-sized VLDL par-
ticles was associated with increasing baseline Lp(a) con-
centrations (Pearson correlation coefficient − 0.5 [− 0.8,
− 0.06]) (Fig. 2).
The correlations between baseline Lp(a) concentra-
tions and reduction in other VLDL particles, including
extremely large, very large, large, small and very small
VLDLs, were − 0.1 [− 0.6, 0.3], − 0.03 [− 0.4, 0.4], − 0.3
Fig. 1 Mean difference in lipoprotein particle concentrations between evolocumab and palacebo group, adjusting for pre-treatment lipoprotein
particle concentrations. Circles represent the posterior mean difference. Lines refer to the 95% credible intervals
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[− 0.7, 0.2], − 0.1 [− 0.7, 0.6], and 0.2 [− 0.3, 0.7],
respectively.
Discussion
Here, we report that evolocumab markedly decreases
VLDL particle concentrations in addition to lowering
LDL-C in patients with elevated Lp(a). In particular, we
identified that the extent of VLDL reduction was
dependent on the baseline Lp(a) level, suggesting a
marked effect of evolocumab on VLDL metabolism in
subjects with elevated Lp(a).
Overall evolocumab resulted in a 17% reduction of
Lp(a), a 67% reduction of LDL-C and a 21% reduction of
triglycerides. Metabolomic consequences of PCSK9 in-
hibition with evolocumab were similar to those induced
by genetic inhibition of PCSK9 and statin therapy [17,
20]. The major metabolic effects of PCSK9 inhibition
were on apoB containing lipoproteins and their lipid
contents. We observed that evolocumab treatment re-
sulted in decreasing concentration of very large HDL
particles and increasing concentrations of medium sized
HDL particles. Although our observation is consistent
with a recent study of evolocumab on lipoprotein parti-
cles, there is no evidence suggesting that PCSK9 modu-
lates HDL particle production or clearance [21]. Future
studies are needed to investigate the role of PCSK9 in
HDL metabolism. There was little effect on other circu-
lating metabolites such as amino acids and ketone bod-
ies. In contrast to genetic inhibition of PCSK9 and statin
therapy that had much larger effects on LDL particles
than VLDL particles, we observed that evolocumab
treatment induced a more substantial reduction in
VLDL particles compared to LDL particles. Although we
observed substantial reduction in extremely and very
large VLDL particle concentrations, the reduction of tri-
glycerides was modest. This is because the absolute con-
centrations of triglycerides in these two VLDL particles
were very low, and the VLDLs of medium and small size
were the main carriers of triglycerides (Fig. S5). With
the help of detailed NMR metabolomics, we were able to
Fig. 2 Reduction of medium VLDL particles correlated with baseline lipoprotein(a) concentrations. Every circle represents the posterior mean
reduction of medium VLDL particle concentration and the posterior mean of baseline lipoprotein(a) in a patient treated with evolocumab. The
vertical and horizontal bar represents the 95% credible interval. The blue dashed line represented the average percentage (50%) change in
medium VLDL particle after evolocumab treatment
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visualize the changes in VLDL particles even though the
overall change of triglycerides was modest. However,
since this study focused on the subjects with elevated
Lp(a), future studies are required to elucidate if evolocu-
mab has similar effect on VLDL particles in subjects
without elevated Lp(a). Our multivariate analysis showed
that Lp(a) lowering did not correlate with particle con-
centration reduction in any of the 14 lipoprotein sub-
classes, suggesting alternative pathways for Lp(a)
clearance, such as scavenger receptor class B type I (SR-
BI) [22] or the plasminogen receptor [23]. Interestingly,
we identified that subjects with higher baseline Lp(a)
showed a larger reduction in medium VLDL particle
concentrations after treatment with evolocumab. We ob-
served that subjects with higher baseline Lp(a) also
showed tendency to have a larger reduction in extremely
large and large VLDL particle concentrations after treat-
ment with evolocumab. However, those tendencies had
large uncertainty due to the fact that the number of
these VLDL particles present after treatment was below
the detection limit, precluding assessment of correlations
(Fig. S6). The number of medium VLDL particles was
sufficiently high to accurately assess the relationship be-
tween its reduction and baseline Lp(a) levels. Surpris-
ingly, we did not observe a similar relationship between
baseline Lp(a) and reduction in small and very small
VLDL particles, suggesting that Lp(a) may not influence
catabolism of these two VLDL particles.Our observation
is in line with the association between the Lp(a)-raising
genotype and decreasing concentrations of extremely
large, very large, large and medium VLDL particles, but
not small and very small VLDL particles [16]. Lp(a) par-
ticles can bind noncovalently to triglyceride-rich lipopro-
teins (TRL), forming a Lp(a)-TRL complex which was
suggested to facilitate receptor-mediated uptake [24, 25].
This process may be particularly important in our sub-
jects with high Lp(a), since they may have a large
amount of the Lp(a)-TRL complex. Together with the
supraphysiological abundance of lipoprotein receptors
induced by evolocumab treatment, these two factors
may underlie the massive reduction of VLDL particles.
On the other hand, apo(a) can be recycled to the extra-
cellular space and bind to apoB-containing particles
again, resulting in moderate reduction of Lp(a) [23].
Based on the above, we hypothesize that the large effect
of evolocumab on VLDL particles in subjects with ele-
vated Lp(a) is due to abundant Lp(a)-TRL complex in
these patients. Future studies are required in order to
test our hypothesis.
Strengths and limitations
Our study provided the first NMR metabolomics data
for a PCSK9 inhibition trial. The detailed metabolomic
profiling not only allowed us to reveal systemic effects of
PCSK9 inhibition, but also to assess the relationship be-
tween Lp(a) lowering and 14 lipoprotein subclasses. We
did not detect statistically significant correlations be-
tween Lp(a) lowering and reduction in lipoprotein sub-
classes probably due to the small number of participants
and considerable missing data in some lipoprotein sub-
classes. We feel it is worth to apply the multilevel multi-
variate model developed in this study in a larger clinical
trial to improve our understanding of interrelationship
between Lp(a) lowering and metabolism of other lipo-
protein subclasses. Another limitation of this study is
that we exclusively focused on the patients with elevated
Lp(a) (≥ 125 nmol/L), in a future study it will be interest-
ing to see if evolocumab treatment will result in similar
effects on triglyceride-rich VLDL particles in patients
with less elevated Lp(a) (for example ≥ 30 mg/dL).
Conclusions
In conclusion, our NMR metabolomic profiling revealed
that evolocumab treatment in patients with high Lp(a)
markedly decreases VLDLs in addition to the well known
effect on LDLs. Moreover, we found that the extent of
VLDL reduction was dependent on the baseline Lp(a)
level. Our findings suggest a marked effect of evolocumab
on VLDL metabolism in subjects with elevated Lp(a).
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